| Name | Title | Contact Details |
|---|---|---|
Marc Bellisario |
Sr. Director, R&D Program Management | Profile |
Michael Saporito |
Vice President of Research and Preclinical Development | Profile |
Michael Barr |
Sr Director Human Resources - Marinus Pharmaceutical | Profile |
Steven Pfanstiel |
Chief Financial Officer | Profile |
Scott Braunstein |
Chief Executive Officer | Profile |
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.
Sisu Stamina is a company that offers energy chews designed to enhance physical and cognitive performance. Their products are made with potent, clean ingredients to fuel the builders of tomorrow.
BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Global Medical Institutes is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.